A Safety and Dose-finding Study of JNJ-26483327, a Drug in Development for Cancer, for Patients With Advanced and/or Refractory Solid Malignancies.

Clinical trial NCT00676299 · COMPLETED

Trial details

NCT number: NCT00676299
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Protein Kinase Inhibitors Antineoplastic Protocols Clinical Trial, Phase 1 Maximum Tolerated Dose Pharmacokinetics Advanced Malignancies Solid Malignancies

Start date: 2006-08-01
Enrollment: 19

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.